

Continuing vs. Suspending ACE inhibitors & ARBs in COVID-19: The BRACE CORONA Trial

OBJECTIVE: To evaluate suspending compared with continuing angiotensin-converting enzyme inhibitors(ACEI) or angiotensin-receptor blockers(ARB) among patients hospitalized with COVID-19



659 patients from 29 sites in Brazil


Patients with diabetes: 33%

follow-up: 30 days



Hospitalized patients

+



Infected with COVID-19

+



Chronically using an ACEI or ARB


Continued use of
ACEI/ARB



1:1 Randomization



Temporary suspension of
ACEI/ARB



All-cause death at 30 days:

Continued use of ACEI/ARB

2.8%

Temporary suspension of ACEI/ARB

2.7%

p = 0.95



Because there is **no clinical benefit from routinely suspending ACEI/ARB** in hospitalized patients with mild-moderate COVID-19, they **should generally continued for those with an indication.**